Cargando…

Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan

BACKGROUND: Rhabdomyosarcoma is the most common soft tissue sarcoma in children, but rare in adults. Para-meningeal rhabdomyosarcoma in head and neck (PM-HNRMS) is less applicable for surgery due to the anatomic reason. PM-HNRMS has a poor prognosis in children. However, its clinical outcomes remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuchihashi, Kenji, Ito, Mamoru, Arita, Shuji, Kusaba, Hitoshi, Kusano, Wataru, Matsumura, Takashi, Kitazono, Takafumi, Ueno, Shohei, Taguchi, Ryosuke, Yoshihiro, Tomoyasu, Doi, Yasuhiro, Arimizu, Kohei, Ohmura, Hirofumi, Kajitani, Tatsuhiro, Nio, Kenta, Nakano, Michitaka, Oshima, Kotoe, Tamura, Shingo, Shirakawa, Tsuyoshi, Shimokawa, Hozumi, Uchino, Keita, Hanamura, Fumiyasu, Okumura, Yuta, Komoda, Masato, Isobe, Taichi, Ariyama, Hiroshi, Esaki, Taito, Hashimoto, Kazuki, Komune, Noritaka, Matsuo, Mioko, Matsumoto, Keiji, Asai, Kaori, Yoshitake, Tadamasa, Yamamoto, Hidetaka, Oda, Yoshinao, Akashi, Koichi, Baba, Eishi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617040/
https://www.ncbi.nlm.nih.gov/pubmed/37904096
http://dx.doi.org/10.1186/s12885-023-11528-4
Descripción
Sumario:BACKGROUND: Rhabdomyosarcoma is the most common soft tissue sarcoma in children, but rare in adults. Para-meningeal rhabdomyosarcoma in head and neck (PM-HNRMS) is less applicable for surgery due to the anatomic reason. PM-HNRMS has a poor prognosis in children. However, its clinical outcomes remain unclear in adults due to the rarity. Further, there is almost no detailed data about salvage therapy. METHODS: We retrospectively examined the adult patients with PM-HNRMS treated at institutions belonging to the Kyushu Medical Oncology Group from 2009 to 2022. We evaluated the overall survival (OS) and progression-free survival (PFS) of the patients who received a first-line therapy. We also reviewed the clinical outcomes of patients who progressed against a first-line therapy and received salvage therapy. RESULTS: Total 11 patients of PM-HNRMS received a first-line therapy. The characteristics were as follows: median age: 38 years (range 25 – 63 years), histology (alveolar/spindle): 10/1, and risk group (intermediate/high): 7/4. As a first-line therapy, VAC and ARST0431-based regimen was performed in 10 and 1 patients, respectively. During a first-line therapy, definitive radiation for all lesions were performed in seven patients. The median PFS was 14.2 months (95%CI: 6.0 – 25.8 months): 17.1 months (95%CI: 6.0 – not reached (NR)) for patients with stage I-III and 8.5 months (95%CI: 5.2 – 25.8 months) for patients with stage IV. The 1-year and 3-year PFS rates were 54.5% and 11.3% for all patients. Median OS in all patients was 40.8 months (95%CI: 12.1 months–NR): 40.8 months (95%CI: 12.1 – NR) for patients with stage I-III and NR for patients with stage IV. The 5-year OS rate was 48.5% for all patients. Among seven patients who received salvage therapy, three are still alive, two of whom remain disease-free for over 4 years after completion of the last therapy. Those two patients received multi-modal therapy including local therapy for all detected lesions. CONCLUSION: The cure rate of adult PM-HNRMS is low in spite of a first-line therapy in this study. Salvage therapy might prolong the survival in patients who received the multi-modal therapy including local therapy for all detected lesions.